The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.
 
Kei Muro
Honoraria - Chugai Pharma; Takeda; Yakult Honsha
Consulting or Advisory Role - Takeda
 
Hiroyuki Uetake
No Relationships to Disclose
 
Katsuya Tsuchihara
Honoraria - Chugai Pharma; Eisai; Fujifilm; Merck Serono; Taiho Pharmaceutical; Takeda
 
Kohei Shitara
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Novartis; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bayer (Inst); Chugai Pharma (Inst); Lilly (Inst); Takeda (Inst)
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb Japan (Inst)
 
Eiji Oki
Speakers' Bureau - Chugai Pharma; Takeda; Yakult Honsha
 
Takeo Sato
No Relationships to Disclose
 
Takeshi Naitoh
Consulting or Advisory Role - Johnson & Johnson; Takeda; TERUMO
Speakers' Bureau - Chugai Pharma; Covidien; Johnson & Johnson
Research Funding - Ajinomoto (Inst)
 
Yoshito Komatsu
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Takeshi Kato
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma; Yakult Honsha
Expert Testimony - Lilly
Travel, Accommodations, Expenses - Eisai
 
Kouji Iwasaki
Employment - Takeda
 
Junpei Soeda
Employment - Takeda
 
Masamitsu Hihara
Employment - Takeda
 
Takeharu Yamanaka
Honoraria - Chugai Pharma; Takeda
 
Atsushi Ochiai
No Relationships to Disclose
 
Takayuki Yoshino
Research Funding - Sumitomo Dainippon (Inst)